Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06168552

Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer — CISPD-6  

Resectable Pancreatic Adenocarcinoma Clinical Trial

Official title:
Exploratory Clinical Study of Fluorescent Navigation Technology Based on Anti-EGFR Antibody-IR800CW Novel Imaging Agent in Radical Resection of Pancreatic Cancer

Clinical Trial Summary

This study intends to design the prospective, exploratory, single center clinical study, using targeted EGFR fluorescence imaging agent (anti-EGFR-IR800CW) and fluorescent navigation technology, in its lymph node tracing, intraoperative tumor localization, accurate determination of resection margin, and explore its clinical significance in radical surgical resection of pancreatic cancer.

Clinical Trial Description

The overall prognosis of pancreatic cancer is poor. For resectable patients, adjuvant chemotherapy is performed after surgery, which has become the standard and standard treatment recommended by various guidelines. Preoperative neoadjuvant therapy is proved to improve the R0 resection rate and reduce the lymph node metastasis rate, thus prolonging the postoperative recurrence-free survival time and increasing the survival benefit of patients. But despite adequate preoperative and postoperative treatment, the patient benefit remains limited. In pancreatic cancer surgery, improving the R0 resection rate, increasing the positive lymph node resection rate, and accurately identifying small metastases to accurately stage, can improve the prognosis of patients to a certain extent. Therefore, this study intends to design the prospective, exploratory, single center clinical study, using targeted EGFR fluorescence imaging agent (anti-EGFR-IR800CW) and fluorescent navigation technology, in its lymph node tracing, intraoperative tumor localization, accurate determination of resection margin, and explore its clinical significance in radical surgical resection of pancreatic cancer. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06168552
Study type Interventional
Source Zhejiang University
Contact Tingbo Liang, PhD
Phone +86 19941463683
Email liangtingbo@zju.edu.cn
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date December 15, 2023
Completion date December 15, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT04940286 - Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer Phase 2
Enrolling by invitation NCT05754788 - Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis
Recruiting NCT05066802 - A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma Phase 2
Recruiting NCT04858334 - APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation Phase 2
Completed NCT00600002 - Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma Phase 1
Recruiting NCT03251365 - Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer Phase 2/Phase 3
Not yet recruiting NCT06423326 - Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer Phase 2
Recruiting NCT04340141 - Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer Phase 3
Recruiting NCT05275075 - Identify microRNAs in Cachexia in Pancreatic Carcinoma
Completed NCT03273374 - Intraoperative Radiation Therapy for Resectable Pancreatic Cancer N/A
Not yet recruiting NCT04915417 - Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma N/A